"GPI-Linked Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of lipid-linked proteins that contain a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE which holds them to the CELL MEMBRANE.
| Descriptor ID |
D058851
|
| MeSH Number(s) |
D12.776.395.550.448 D12.776.543.484.500 D12.776.543.550.418
|
| Concept/Terms |
GPI-Linked Proteins- GPI-Linked Proteins
- GPI Linked Proteins
- Proteins, GPI-Linked
- GPI-Linked Membrane Proteins
- GPI Linked Membrane Proteins
- Membrane Proteins, GPI-Linked
- Proteins, GPI-Linked Membrane
- Glycosylphosphatidylinositol Linked Proteins
- Linked Proteins, Glycosylphosphatidylinositol
- Proteins, Glycosylphosphatidylinositol Linked
|
Below are MeSH descriptors whose meaning is more general than "GPI-Linked Proteins".
Below are MeSH descriptors whose meaning is more specific than "GPI-Linked Proteins".
This graph shows the total number of publications written about "GPI-Linked Proteins" by people in this website by year, and whether "GPI-Linked Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 4 | 4 |
| 2011 | 2 | 1 | 3 |
| 2013 | 1 | 4 | 5 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 4 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 2 | 4 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "GPI-Linked Proteins" by people in Profiles.
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
-
BST2 facilitates activation of hematopoietic stem cells through ERK signaling. Exp Hematol. 2024 Dec; 140:104653.
-
Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia. Cancer Prev Res (Phila). 2024 Oct 01; 17(10):457-470.
-
Urinary dipeptidase 1 and trefoil factor 1 are promising biomarkers for early diagnosis of colorectal cancer. J Gastroenterol. 2024 07; 59(7):572-585.
-
Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin. Cell Rep. 2023 10 31; 42(10):113254.
-
Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy. Cancer Immunol Res. 2023 10 04; 11(10):1314-1331.
-
Ropivacaine-Epinephrine-Clonidine-Ketorolac Cocktail as a Local Anesthetic for Lumbar Decompression Surgery: A Single Institutional Experience. World Neurosurg. 2023 08; 176:e515-e520.
-
CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Oncogene. 2022 Feb; 41(7):971-982.
-
Elucidating the clinical spectrum and molecular basis of HYAL2 deficiency. Genet Med. 2022 03; 24(3):631-644.
-
STAT3 Gain-of-Function Mutations Underlie Deficiency in Human Nonclassical CD16+ Monocytes and CD141+ Dendritic Cells. J Immunol. 2021 11 15; 207(10):2423-2432.